Phase I Study of Chemokine and Cytokine Gene-modified Autologous Neuroblastoma Cells for Treatment of Relapsed/refractory Neuroblastoma Using an Adenoviral Vector
Overview
Authors
Affiliations
Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future.
Morandi F, Sabatini F, Podesta M, Airoldi I Vaccines (Basel). 2021; 9(1).
PMID: 33450862 PMC: 7828327. DOI: 10.3390/vaccines9010043.
Polymeric oncolytic adenovirus for cancer gene therapy.
Choi J, Lee Y, Yun C, Kim S J Control Release. 2015; 219:181-191.
PMID: 26453806 PMC: 4668934. DOI: 10.1016/j.jconrel.2015.10.009.
Immunotherapy in pediatric malignancies: current status and future perspectives.
Capitini C, Otto M, DeSantes K, Sondel P Future Oncol. 2014; 10(9):1659-78.
PMID: 25145434 PMC: 4793725. DOI: 10.2217/fon.14.62.
Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Heczey A, Louis C Discov Med. 2013; 16(90):287-94.
PMID: 24333408 PMC: 4106238.
Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site.
Zhou Q, Johnson B, Orentas R Cell Immunol. 2007; 245(2):91-102.
PMID: 17543914 PMC: 1949498. DOI: 10.1016/j.cellimm.2007.04.004.